Twist Bioscience to Present at the UBS Global Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--May 16, 2019--
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder, will present at the UBS Global Healthcare Conference on Monday, May 20 th at 11:30 a.m. ET.
This presentation will be webcast live and can be accessed by visiting the “Presentations” page of the investor relations section of the company’s website here. A replay of the presentation will be archived for a period of 90 days following the conclusion of the live event.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190516005297/en/
CONTACT: Investor Contact:
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT NANOTECHNOLOGY HEALTH BIOTECHNOLOGY GENETICS
SOURCE: Twist Bioscience Corporation
Copyright Business Wire 2019.
PUB: 05/16/2019 08:00 AM/DISC: 05/16/2019 08:01 AM